Novel Opioid Has Faster Onset of Pain Relief, Leads to Fewer Adverse Events

San Francisco—An investigational agent designed to improve conventional opioid pharmacology has demonstrated efficacy and safety, as well as faster onset of action, in a pair of pivotal trials.

Compared with placebo, patients receiving IV oliceridine (TRV130, Trevena), a novel mu-receptor G protein pathway–selective (mu-GPS) modulator, experienced superior relief following bunionectomy or abdominoplasty. Oliceridine also showed favorable trends in respiratory safety and upper